Trials / NCT06395285
Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients
Recruiting now Phase 1 Supplement / diet
- Sponsor
- Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
- Treatment
- DF-003
- Gene
- Not stated
- Conditions
- ROSAH
- Ages
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Started
- 2025-05-27
- Main results expected
- 2026-07
- Results posted
- Not yet
- Record last updated
- 2026-06-05
What the study is testing
The purpose of this study is to evaluate the safety and tolerability of DF-003 in retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndrome patients.
Where it runs
Australia (1)
- Save Sight Institute - University of Sydney Eye Hospital, Sydney, New South Wales (recruiting now)
China (1)
- Peking Union Medical College Hospital, Beijing (recruiting now)
United States (3)
- National Institutes of Health Clinical Center, Bethesda, Maryland (withdrawn)
- Duke Eye Center - Duke University Hospital, Durham, North Carolina (recruiting now)
- John A. Moran Eye Center - University of Utah Health, Salt Lake City, Utah (recruiting now)